kyron.bio
kyron.bio’s aims to address issues in biologic drug development. The company is focused on controlling sugar molecules, known as glycans, on the surface of drugs to address issues such as varying efficacy and the risk of side effects.
kyron.bio has raised €5.5M across 1 funding round from 5 investors, most recently a round in May 2025. Based in Paris, France; active in Healthtech. Data as of 28 Oct 2026.
Paris, Francewww.kyron.bio ↗
Total raised
€5.5M
€5,500,000
Funding rounds
1
Investors
5
distinct backers
Active since
2025-05
latest 2025-05
Funding by year
EUR raised per yearkyron.bio — funding by year — interactive chart.
Data table
| kyron.bio — funding by year | |
|---|---|
| 2025 | €5.5M |
Signals
High confidenceRaise-next likelihood42
base rate 30% for Other
- ▲ In typical raise window
- ▼ Low backer re-investment
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-05-28 | Other | €5.5M | Angel Investors,Entrepreneur First,HCVC,Saras Capital,Verve Ventures | View deal → |
Investors
5Related news
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData